| HOME >> MEDICINE >> TECHNOLOGY |
38,125
20,864Trade receivable
607
—Receivable from collaboration partner
65
678Inventories
786
58Prepaid expenses and other current assets
1,082
711Restricted cash
290
40Total current assets
49,660
52,046Property and equipment, net
809
739Restricted cash
120
120Other assets
261
—Total assets
$ 50,850
$ 52,905Liabilities and Stockholders' (Deficit) Equity Current liabilities:Accounts payable
$ 1,544
$ 65Accrued compensation
1,867
2,157Accrued license fee
—
1,213Accrued research and development
582
670Other accrued expenses
3,011
1,222Deferred product revenue, net
577
—Deferred collaboration revenue
7,242
7,242Long term obligations—current portion
2,222
—Notes payable—current portion
—
191Total current liabilities
17,045
12,760Non-current liabilities:Deferred collaboration revenue
32,359
39,601Deferred rent
115
291Long term obligations
42,622
—Total non-current liabilities
75,096
39,892Commitments and contingencies Stockholders' (deficit) equity:Common stock, $0.001 par value;
100,000,000 shares authorized at December 31, 2010 and 2009;
17,869,108 and 17,725,959 shares issued and outstanding at December 31,
2010, and 2009, respectively
18
18Additional paid-in capital
215,220
212,254Accumulated other comprehensive loss
(2)
(8)Accumulated deficit
(256,527)
(212,011)Total stockholders'
'/>"/>
| SOURCE NeurogesX, Inc. Copyright©2010 PR Newswire. All rights reserved |